Journal
EBIOMEDICINE
Volume 31, Issue -, Pages 17-24Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.ebiom.2018.04.020
Keywords
Tumor microenvironment; Oncolytic viruses; Cancer immunotherapies; Combination therapies
Funding
- Terry Fox Research Foundation [2015-0889]
- Canadian Institutes of Health Research [153187]
- Canadian Institutes of Health Research Frederick Banting and Charles Best Master's Award
- Ontario Institute for Cancer Research
- Ottawa Regional Cancer Foundation
Ask authors/readers for more resources
Oncolytic virus (OV) therapy is potentially a game-changing cancer treatment that has garnered significant interest due to its versatility and multi-modal approaches towards tumor eradication. In the field of cancer immunotherapy, the immunological phenotype of the tumor microenvironment (TME) is an important determinant of disease prognosis and therapeutic success. There is accumulating data that OVs are capable of dramatically altering the TME immune landscape, leading to improved antitumor activity alone or in combination with assorted immune modulators. Herein, we review how OVs disrupt the immunosuppressive TME and can be used strategically to create a pro-immune microenvironment that enables and promotes potent, long-lasting host antitumor immune responses. (C) 2018 The Authors. Published by Elsevier B.V.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available